{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"78","upperLimit":"97","value":"91"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"48"}],"units":"Participants"}],"description":"Overall survival (OS) was measured from enrollment to death from any cause. OS was estimated using the product-limit method of Kaplan and Meier along with the Greenwood estimator of standard error.","dispersionType":"95% Confidence Interval","groups":[{"description":"INDUCTION: Patients receive cyclophosphamide IV and doxorubicin IV on day 1, etoposide IV on days 1-3, and prednisone PO on days 1-5. Patients also receive brentuximab vedotin IV over approximately 30 minutes on day 1. Treatment repeats every 21 days for up to 6 cycles (or for up to 5 cycles for patients who received 1 cycle of CHOP-like or CHP-BV therapy prior to induction, per investigator's discretion) in the absence of disease progression or unacceptable toxicity.\n\nCONSOLIDATION: Between 30-60 days post-consolidative autologous stem cell therapy, post-consolidative radiation therapy, or after completing induction cycle 6 (cycle 5 for patients who qualify for receiving 5 cycles of CHEP-BV instead of 6), patients with objective response (complete response or partial response) receive brentuximab vedotin IV over approximately 30 minutes on day 1. Treatment repeats every 21 days for up to 10 cycles in the absence of disease progression or unacceptable toxicity.\n\nBrentuximab Vedotin: Given IV\n\nCyclophosphamide: Given IV\n\nDoxorubicin: Given IV\n\nDoxorubicin Hydrochloride: Given IV\n\nEtoposide: Given IV\n\nEtoposide Phosphate: Given IV\n\nLaboratory Biomarker Analysis: Correlative studies\n\nPrednisone: Given PO","id":"OG000","title":"Treatment (CHEP-BV)"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"The time from enrollment to death from any cause assessed up to 1 year.","title":"Overall Survival at 1 Year","type":"SECONDARY","unitOfMeasure":"percentage of survival probability"}